ES2492681T3 - Método cromatográfico para purificar proteínas que contienen FC - Google Patents

Método cromatográfico para purificar proteínas que contienen FC Download PDF

Info

Publication number
ES2492681T3
ES2492681T3 ES11700457.2T ES11700457T ES2492681T3 ES 2492681 T3 ES2492681 T3 ES 2492681T3 ES 11700457 T ES11700457 T ES 11700457T ES 2492681 T3 ES2492681 T3 ES 2492681T3
Authority
ES
Spain
Prior art keywords
protein
concentration
sought
mobile phase
stationary phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11700457.2T
Other languages
English (en)
Inventor
Christian Eckermann
Dorothee Ambrosius
Franz Nothelfer
Thomas Rathjen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2492681T3 publication Critical patent/ES2492681T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Método para disminuir las impurezas de una composición que contiene una proteína con el dominio Fc de una inmunoglobulina (proteína buscada) mediante una cromatografía de proteína A que consta de las siguientes etapas: a) uso de una fase móvil que contiene la proteína buscada sobre una fase estacionaria que lleva la proteína A, en unas condiciones en que la proteína buscada se fija a la fase estacionaria; b) uso de un tampón de lavado con un pH comprendido entre 5 y 8 como fase móvil, que lleva como aditivos i) arginina a una concentración de 0,1 - 1 mol/l, ii) cloruro sódico a una concentración de 0,2 hasta 2 mol/l, iii) un alcohol elegido del grupo formado por isopropanol, n-propanol y etanol a una concentración del 5 - 30% (p/v) y iv) polivinilpirrolidona o un detergente a una concentración del 0,05 - 2% (p/v); c) uso de un tampón de elución como fase móvil, en unas condiciones en que la proteína buscada es eluida de la fase estacionaria.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES11700457.2T 2010-01-22 2011-01-21 Método cromatográfico para purificar proteínas que contienen FC Active ES2492681T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10151416 2010-01-22
EP10151416 2010-01-22
EP10171975 2010-08-05
EP10171975 2010-08-05
PCT/EP2011/050817 WO2011089212A1 (de) 2010-01-22 2011-01-21 Chromatographisches verfahren zur aufreinigung von fc enthaltenden proteinen

Publications (1)

Publication Number Publication Date
ES2492681T3 true ES2492681T3 (es) 2014-09-10

Family

ID=43598239

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11700457.2T Active ES2492681T3 (es) 2010-01-22 2011-01-21 Método cromatográfico para purificar proteínas que contienen FC

Country Status (11)

Country Link
US (1) US9284347B2 (es)
EP (1) EP2526114B1 (es)
JP (1) JP5567691B2 (es)
KR (1) KR101753569B1 (es)
CN (1) CN102712673B (es)
AU (1) AU2011208659B2 (es)
CA (1) CA2784959C (es)
DK (1) DK2526114T3 (es)
ES (1) ES2492681T3 (es)
SG (1) SG182553A1 (es)
WO (1) WO2011089212A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133191A1 (en) * 2010-04-23 2011-10-27 Serum Institute Of India, Ltd. Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
JP6366502B2 (ja) * 2011-06-01 2018-08-01 ノバルティス アーゲー アフィニティクロマトグラフィーのための、洗浄溶液および方法
US9914770B2 (en) 2013-04-30 2018-03-13 Intas Pharmaceuticals Ltd Cloning, expression and purification method for the preparation of ranibizumab
AR096713A1 (es) 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
MA40232A (fr) * 2014-06-13 2017-04-19 Lupin Ltd Procédé de purification de la protéine de fusion tnfr:fc
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
RU2670166C1 (ru) 2014-12-31 2018-10-18 ЭлДжи КЕМ, ЛТД. Способ получения слитого белка tnfr-fc с заданным содержанием примесей
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN109311949B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 储存分离基质的方法
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
WO2017194593A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
BR112020009259A2 (pt) * 2017-11-14 2020-10-20 Bio-Sourcing S.A. purificação de anticorpo
EP3546475A1 (en) * 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
WO2020125757A1 (en) * 2018-12-21 2020-06-25 Wuxi Biologics (Shanghai) Co., Ltd. A method for improving aggregate removal by protein a chromatography
CN111333776B (zh) * 2020-03-20 2021-11-09 暨南大学 一种氮杂环类有机聚合物整体材料及制备与应用
WO2024017826A2 (en) * 2022-07-19 2024-01-25 Glaxosmithkline Intellectual Property Development Limited Methods for purifying recombinant polypeptides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874218A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US5585246A (en) * 1993-02-17 1996-12-17 Biometric Imaging, Inc. Method for preparing a sample in a scan capillary for immunofluorescent interrogation
ATE417858T1 (de) * 2002-02-05 2009-01-15 Genentech Inc Proteinaufreinigung
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
WO2007059473A2 (en) * 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Methods for the production and purification of adenoviral vectors
AU2007204987B2 (en) 2006-01-06 2011-11-24 Amgen Inc. Methods and systems for isolating target molecules from complex solutions by column-chromatography using eluants containing organic solvents
US8263750B2 (en) * 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
CL2007002615A1 (es) * 2006-09-08 2008-04-18 Wyeth Corp Metodos para aislar o purificar un producto que comprende poner el producto enlazado en contacto con al menos una solucion de lavado que comprende arginina y luego eluir el producto; y dicho producto.
KR20110139216A (ko) * 2009-03-11 2011-12-28 와이어쓰 엘엘씨 소형 모듈형 면역약제 단백질의 정제 방법
CA2784278C (en) 2009-12-18 2019-02-26 Novartis Ag Wash solution and method for affinity chromatography

Also Published As

Publication number Publication date
EP2526114A1 (de) 2012-11-28
JP2013517318A (ja) 2013-05-16
CA2784959A1 (en) 2011-07-28
AU2011208659B2 (en) 2015-05-28
KR20120118013A (ko) 2012-10-25
WO2011089212A1 (de) 2011-07-28
DK2526114T3 (da) 2014-09-29
US9284347B2 (en) 2016-03-15
US20130197197A1 (en) 2013-08-01
CN102712673B (zh) 2014-04-30
SG182553A1 (en) 2012-08-30
KR101753569B1 (ko) 2017-07-04
CA2784959C (en) 2018-06-26
JP5567691B2 (ja) 2014-08-06
HK1174044A1 (en) 2013-05-31
AU2011208659A1 (en) 2012-07-19
CN102712673A (zh) 2012-10-03
EP2526114B1 (de) 2014-06-18

Similar Documents

Publication Publication Date Title
ES2492681T3 (es) Método cromatográfico para purificar proteínas que contienen FC
RU2013156669A (ru) Промывочный раствор и способ аффинной хроматографии
AR062570A1 (es) Proceso para la purificacion de las proteinas que contienen fc
ES2572352T3 (es) Procedimiento de aislamiento y purificación de proteína diana exenta de proteínas priónicas (PrPSC)
ES2500066T3 (es) Anticuerpos frente a ferroportina y métodos de uso
MX2019000898A (es) Amortiguador de lavado de cromatografia de afinidad.
ES2524786T3 (es) Uso de quelantes inmovilizados para purificación de proteínas recombinantes por cromatografía de iones metálicos inmovilizados y método de purificación de proteínas recombinantes
CL2012001966A1 (es) Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis.
MX395730B (es) Uso de lavados alcalinos durante la cromatografia para remover impurezas.
RU2012130151A (ru) Промывочный раствор и способ промывки для аффинной хроматографии
EA201290076A1 (ru) Специфичный сорбент для связывания белков и пептидов и способ выделения с его использованием
AR062711A1 (es) Lavado de arginina en l a purificacion de proteinas usando cromatografia de afinidad
ES2585580T3 (es) Péptidos novedosos antienvejecimiento y composición cosmética y/o farmacéutica que los contiene
BRPI0806737A8 (pt) uso de sistema de renomeação de registrador para encaminhar resultados intermediários entre instruções constituintes de uma instrução expandida
GB2515984A (en) Chromatographic materials
EA201592192A1 (ru) Способ очистки моноклональных антител
BR112015027812A2 (pt) processo contínuo de multietapa para purificação de anticorpos
BR112015014751A2 (pt) anticorpos anti-tau humanos
MX363380B (es) Formulacion de anticuerpos.
AR085138A1 (es) VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
AR070633A1 (es) Metodos para modificar el punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en la region de determinacion de la complementariedad (cdr)
AR097791A1 (es) Formulaciones de anticuerpos anti-pdl1
PE20191815A1 (es) Formulaciones acuosas estables de adalimumab
BR112015011749A2 (pt) controle do uso de um único espaço de estacionamento para múliplos veículos utilizando múltiplas câmeras
MX2019015304A (es) Amortiguador de lavado para cromatografia de intercambio cationico.